Publications by authors named "Chad Swanson"

Vertebrate genomes contain lower than expected frequencies of the CpG dinucleotide. Consequently, many vertebrate viruses have evolved to mimic this composition, possibly in order to evade host antiviral defences (Greenbaum et al., 2008).

View Article and Find Full Text PDF

The shortcomings of current direct-acting anti-viral therapy against human cytomegalovirus (HCMV) has led to interest in host-directed therapy. Here we re-examine the use of interferon proteins to inhibit HCMV replication utilizing both high and low passage strains of HCMV. Pre-treatment of cells with interferon alpha (IFNα) was required for robust and prolonged inhibition of both low and high passage HCMV strains, with no obvious toxicity, and was associated with an increased anti-viral state in HCMV-infected cells.

View Article and Find Full Text PDF

Rationale: COVID-19 has fundamentally changed the practice of Emergency Medicine (EM). Care delivery on the front lines has historically depended upon ostensibly reliable input-output models for staffing, supplies, policies, and therapies. Challenged by the complexity of healthcare during the pandemic, the fallibility of these reductionist models was quickly revealed.

View Article and Find Full Text PDF
Article Synopsis
  • Bayesian clinical trial designs are becoming more prevalent, endorsed by the FDA, and they enhance drug development efficiency and clinical trial accuracy, especially with incomplete data.
  • The study focuses on the bayesian approach used in the lecanemab trial 201, aimed at identifying the effective dose for treating early Alzheimer's disease while showcasing the benefits of adaptive design and treatment-dependent handling of missing data.
  • In the lecanemab 201 trial, 854 participants were randomly assigned to various treatment doses or a placebo, with the main outcome being the Alzheimer's Disease Composite Clinical Score after 12 months of treatment.
View Article and Find Full Text PDF
Article Synopsis
  • Lecanemab is a monoclonal antibody designed to target specific forms of amyloid in the brain, an element related to Alzheimer's disease, and its ARIA profiles vary among different anti-amyloid treatments.
  • The phase 2 Study 201 was designed to evaluate ARIA occurrences using both core and open-label methods, employing statistical models to analyze the data.
  • Results showed a low incidence of ARIA-E (less than 10%) during treatment, primarily mild-to-moderate and often asymptomatic, with correlations to serum concentrations and higher risk in ApoE4 carriers.*
View Article and Find Full Text PDF

Cellular antiviral factors that recognize viral nucleic acid can inhibit virus replication. These include the zinc finger antiviral protein (ZAP), which recognizes high CpG dinucleotide content in viral RNA. Here, we investigated the ability of ZAP to inhibit the replication of human cytomegalovirus (HCMV).

View Article and Find Full Text PDF

There is a growing interest in the study of human endogenous retroviruses (HERVs) given the substantial body of evidence that implicates them in many human diseases. Although their genomic characterization presents numerous technical challenges, next-generation sequencing (NGS) has shown potential to detect HERV insertions and their polymorphisms in humans. Currently, a number of computational tools to detect them in short-read NGS data exist.

View Article and Find Full Text PDF

The zinc finger antiviral protein (ZAP) inhibits viral replication by directly binding CpG dinucleotides in cytoplasmic viral RNA to inhibit protein synthesis and target the RNA for degradation. ZAP evolved in tetrapods and there are clear orthologs in reptiles, birds, and mammals. When ZAP emerged, other proteins may have evolved to become cofactors for its antiviral activity.

View Article and Find Full Text PDF
Article Synopsis
  • Antibody therapy targeting aggregated β-amyloid (Aβ) is a leading approach for treating Alzheimer's disease, using a detailed model to understand Aβ dynamics and how activated microglia cells clear aggregated Aβ.
  • A quantitative systems pharmacology (QSP) model helps predict Aβ levels in brain imaging (PET scans) and tracks biomarkers in cerebrospinal fluid (CSF) and plasma, incorporating genetic factors like apolipoprotein E genotype.
  • The QSP model can inform the design of clinical trials for various amyloid-targeting treatments, establish dosing schedules, and offer insights into how individual responses to biomarkers can vary in clinical settings.
View Article and Find Full Text PDF
Article Synopsis
  • Lecanemab, a monoclonal antibody targeting soluble Aβ protofibrils, showed significant brain amyloid reduction and slowed decline in early Alzheimer's Disease (AD) during a clinical study involving 856 patients.
  • In a double-blind, placebo-controlled trial and subsequent open-label extension, patients receiving lecanemab demonstrated dose-dependent improvements in brain amyloid levels and cognitive function, whereas those on placebo did not.
  • The study findings suggest that reducing amyloid plaques correlates with clinical benefits, indicating lecanemab's potential as an effective treatment for early AD.
View Article and Find Full Text PDF
Article Synopsis
  • Lecanemab is an experimental antibody designed to target specific forms of amyloid-beta associated with Alzheimer's disease, showing promising results in a phase 2 study involving 856 participants over 18 months.
  • The study employed various statistical methods to analyze the efficacy of lecanemab, all indicating a significant slowing of clinical decline in early Alzheimer's compared to placebo.
  • Sensitivity analyses confirmed the robustness of these findings, demonstrating a consistent treatment effect on cognitive decline across multiple assessment tools at both 12 and 18 months.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates lecanemab, a monoclonal antibody targeting amyloid-beta, in treating early Alzheimer's disease over 18 months.
  • It involved 1,795 participants divided equally between lecanemab and placebo, focusing on cognitive impairment and amyloid levels.
  • Results showed lecanemab users had a smaller increase in cognitive impairment scores compared to the placebo group, indicating potential benefits in early Alzheimer’s treatment.
View Article and Find Full Text PDF

The appearance of new dominant variants of concern (VOC) of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) threatens the global response to the coronavirus disease 2019 (COVID-19) pandemic. Of these, the alpha variant (also known as B.1.

View Article and Find Full Text PDF

Human endogenous retroviruses (HERVs) integrated into the human genome as a result of ancient exogenous infections and currently comprise ∼8% of our genome. The members of the most recently acquired HERV family, HERV-Ks, still retain the potential to produce viral molecules and have been linked to a wide range of diseases including cancer and neurodegeneration. Although a range of tools for HERV detection in NGS data exist, most of them lack wet lab validation and they do not cover all steps of the analysis.

View Article and Find Full Text PDF
Article Synopsis
  • Lecanemab is a monoclonal antibody that targets soluble Aβ aggregates, aiming to treat early Alzheimer's disease by affecting amyloid pathology.
  • The study analyzed how the drug's pharmacokinetics (PK) and pharmacodynamics (PD) influence amyloid plaque measurements through PET scans and blood biomarkers.
  • Results indicate that biweekly dosing of lecanemab is more effective at reducing harmful amyloid levels compared to monthly doses, and that amyloid levels in the brain take longer to return to baseline after stopping treatment than blood biomarkers.
View Article and Find Full Text PDF

Sepsis is a common illness. Immune responses are considered major drivers of sepsis illness and outcomes. However, there are no proven immunomodulator therapies in sepsis.

View Article and Find Full Text PDF
Article Synopsis
  • Alzheimer's disease (AD) begins with a long asymptomatic stage characterized by the accumulation of amyloid beta (Aβ) before clinical symptoms arise; the AHEAD 3-45 Study tests if the drug lecanemab can intervene in this stage to slow decline.
  • Launched in July 2020, the study includes two trials, A3 and A45, targeting cognitively unimpaired individuals aged 55-80, with different dosing based on their Aβ levels noted in PET scans.
  • The study employs innovative recruitment methods to enrich the sample for those with elevated brain amyloid, using various registries and advanced plasma screening techniques to identify suitable participants.
View Article and Find Full Text PDF

Ebola virus (EBOV) causes highly pathogenic disease in primates. Through screening a library of human interferon-stimulated genes (ISGs), we identified TRIM25 as a potent inhibitor of EBOV transcription-and-replication-competent virus-like particle (trVLP) propagation. TRIM25 overexpression inhibited the accumulation of viral genomic and messenger RNAs independently of the RNA sensor RIG-I or secondary proinflammatory gene expression.

View Article and Find Full Text PDF

The antiviral protein ZAP binds CpG dinucleotides in viral RNA to inhibit replication. This has likely led to the CpG suppression observed in many RNA viruses, including retroviruses. Sequences added to retroviral vector genomes, such as internal promoters, transgenes, or regulatory elements, substantially increase CpG abundance.

View Article and Find Full Text PDF
Article Synopsis
  • The zinc finger antiviral protein (ZAP) inhibits virus replication by binding to CpG dinucleotides in viral RNAs, leading to their degradation or halted translation with the help of cofactors like TRIM25 and KHNYN.
  • ZAP has two isoforms, ZAP-L and ZAP-S, which localize differently inside cells and have varying antiviral effectiveness; ZAP-L shows significant activity against ZAP-sensitive HIV-1 due in part to its PARP domain.
  • The CaaX box in ZAP-L is crucial for its localization to membranes where it interacts with cofactors to form an antiviral complex, and the importance of these domains was evidenced by their role in restricting SARS-CoV-2 replication
View Article and Find Full Text PDF

The interactions between a virus and its host are complex but can be broadly categorized as either viral manipulation of cellular functions or cellular responses to infection. These processes begin at the earliest point of contact between virus and cell and frequently result in changes to cellular gene expression, making genome-wide transcriptomics a useful tool to study them. Several previous studies have used transcriptomics to evaluate the cellular responses to human immunodeficiency virus type 1 (HIV-1) infection; however, none have examined events in primary CD4 T cells during the first 24 h of infection.

View Article and Find Full Text PDF

The zinc finger antiviral protein (ZAP) restricts the replication of a broad range of RNA and DNA viruses. ZAP directly binds viral RNA, targeting it for degradation and inhibiting its translation. While the full scope of RNA determinants involved in mediating selective ZAP activity is unclear, ZAP binds CpG dinucleotides, dictating at least part of its target specificity.

View Article and Find Full Text PDF

Many lentiviral vectors used for gene therapy are derived from HIV-1. An optimal vector genome would include only the viral sequences required for transduction efficiency and gene expression to minimize the amount of foreign sequence inserted into a patient's genome. However, it remains unclear whether all of the HIV-1 sequence in vector genomes is essential.

View Article and Find Full Text PDF
Article Synopsis
  • - Lecanemab (BAN2401) is an antibody designed to target forms of amyloid beta linked to Alzheimer's, tested in a double-blind trial comparing it with a placebo in early-stage disease.
  • - The trial aimed to find an effective dose (ED90) that reduces clinical decline by at least 25% compared to placebo, using various assessment scales and brain imaging techniques over 12 and 18 months.
  • - Although the initial 12-month results did not meet the effectiveness threshold, by 18 months, lecanemab showed promising reductions in amyloid levels and clinical decline, while being well-tolerated by participants with a low incidence of adverse effects.
View Article and Find Full Text PDF